Phospholipase levels and serological markers of atherosclerosis 2: An examination of once daily (QD) dosing of A-002 [varespladib] in subjects with stable coronary artery disease

Trial Profile

Phospholipase levels and serological markers of atherosclerosis 2: An examination of once daily (QD) dosing of A-002 [varespladib] in subjects with stable coronary artery disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2010

At a glance

  • Drugs Varespladib (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms PLASMA-2
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2008 Results presented at the 81st Annual Scientific Sessions of the American Heart Association.
    • 03 Jan 2008 Status changed from in progress to completed.
    • 06 Nov 2007 Results are expected in the first quarter of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top